Hybrid (BDBB) interferon-α:: preformulation studies

被引:3
作者
Allen, JD [1 ]
Bentley, D [1 ]
Stringer, RA [1 ]
Lowther, N [1 ]
机构
[1] Novartis Horsham Res Ctr, Drug Preformulat & Delivery Dept, Horsham RH12 5AB, W Sussex, England
关键词
interferon; protein stability; degradation; preformulation; analysis;
D O I
10.1016/S0378-5173(99)00124-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A number of techniques, including RP-HPLC, HP-SEC and SDS-PAGE have been used in the delineation of degradative mechanisms of recombinant hybrid (BDBB) interferon-alpha (IFN-alpha) in the solution phase. Different degradation profiles are found according to medium pH. At pH 4.0 the major routes of degradation are via chemical transformation of the monomeric protein to a species which retains antiviral activity, and by self-proteolytic hydrolysis. At pH 7.6, methionine-oxidation is the major chemical degradative process. Protein aggregation is also a significant route of degradation at the higher pH. The results have assisted in a targeted preformulation screen of potentially stabilising excipients and possible parenteral solution dosage forms have been identified. Preliminary 'real-time' storage data confirm excellent chemical and physical stability of IFN-a in vehicles formulated at pH 7.6 or, especially, pH 4.0 under the proposed shelf conditions. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:259 / 272
页数:14
相关论文
共 22 条
[1]  
ARAWAKA T, 1982, BIOCHEMISTRY-US, V21, P6536
[2]  
EVANS S, 1986, Journal of Parenteral Science and Technology, V40, P83
[3]   ANTIVIRAL ACTIVITY OF A NOVEL RECOMBINANT HUMAN INTERFERON-ALPHA-B/D HYBRID [J].
GANGEMI, JD ;
LAZDINS, J ;
DIETRICH, FM ;
MATTER, A ;
PONCIONI, B ;
HOCHKEPPEL, HK .
JOURNAL OF INTERFERON RESEARCH, 1989, 9 (02) :227-237
[4]  
GEIGERT J, 1989, J PARENT SCI TECHN, V43, P220
[5]  
Hochkeppel H. K., 1992, Drugs of the Future, V17, P899
[6]  
ITRI LM, 1992, CANCER, V70, P940
[7]   CHEMICAL PATHWAYS OF PEPTIDE DEGRADATION .5. ASCORBIC-ACID PROMOTES RATHER THAN INHIBITS THE OXIDATION OF METHIONINE TO METHIONINE SULFOXIDE IN SMALL MODEL PEPTIDES [J].
LI, SH ;
SCHONEICH, C ;
WILSON, GS ;
BORCHARDT, RT .
PHARMACEUTICAL RESEARCH, 1993, 10 (11) :1572-1579
[8]   THE INTERFERONS IN CLINICAL-PRACTICE [J].
LUCIVERO, G .
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 1992, 5 (02) :83-92
[9]   STABILITY OF PROTEIN PHARMACEUTICALS [J].
MANNING, MC ;
PATEL, K ;
BORCHARDT, RT .
PHARMACEUTICAL RESEARCH, 1989, 6 (11) :903-918
[10]  
Meager A., 1987, LYMPHOKINES INTERFER, P129